Status:
RECRUITING
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
Lead Sponsor:
Zhejiang Provincial People's Hospital
Conditions:
Cerebral Microbleeds
Stroke
Eligibility:
All Genders
35+ years
Phase:
PHASE3
Brief Summary
The purpose of this clinical trial is to demonstrate that cilostazol is non-inferior to aspirin in terms of efficacy and safety for the secondary prevention of stroke in patients with acute non-cardio...
Detailed Description
The plan is to enroll patients with acute non-cardioembolic stroke who have concurrent cerebral microbleeds (CMBs). After enrollment, patients will be randomly assigned to either the Cilostazol group ...
Eligibility Criteria
Inclusion
- Acute ischemic stroke (within 1 month of onset)
- Non-cardioembolic stroke
- Presence of cerebral microbleeds (CMBs) confirmed by susceptibility-weighted imaging (SWI)
Exclusion
- Previous diagnosis of cerebral amyloid angiopathy (CAA) according to the Boston 2.0 diagnostic criteria
- History of intracerebral hemorrhage highly suspected to be caused by CAA-related lobar hemorrhage
- Severe adverse reactions (such as active bleeding, severe allergies, etc.) to aspirin or cilostazol in the past, leading to non-compliance with medication
- Requirement for combined anticoagulant therapy
- Requirement for long-term dual antiplatelet therapy (\>1 month)
Key Trial Info
Start Date :
July 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2031
Estimated Enrollment :
848 Patients enrolled
Trial Details
Trial ID
NCT06530537
Start Date
July 18 2024
End Date
August 30 2031
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China, 310014